 
 
A Multicenter, Randomized, Double -Blind, Placebo -Controlled  
Study to Evaluate the Efficacy and Safety of a New Dilution and  
Injection Volume of AbobotulinumtoxinA for the Treatment of  
Moderate to Severe Glabellar Lines  
  
Study ID: [REMOVED] 
  
Protocol  Document date: 2 4Jan 2019  
  
 
Page 1of 79CLINICAL STUDY PROTOCOL
PROTOCOL NUMBER: 43USD1805
CONFIDENTIAL
This document contains confidential, proprietary information
All the information provided to the Investigator and his/her staff and all data obtained through this 
Q-Med AB clinical study protocol are confidential.  The Sponsor reserves all proprietary  rights. 
No information may be disclosed to any third party withou t prior written consent from 
Q-M ed AB .
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:[ADDRESS_522007] OF ABBREVIATIONS AND DEFINITIONS OF TERMS ...........................................................19
1 BACKGROUND AND RATIONALE ..............................................................................................21
1.1 Medical Background and Short Rationale for the Clinical Study ............................................21
1.2 Drug Profile ...................................................................................................................................22
1.3 Target Indication ..........................................................................................................................22
1.4 Risk/Benefit Assessment ................................................................
...............................................22
2 CLINICAL STUDY OBJECTI VES, ENDPOINTS, AND CLINICAL HYPOTHESIS .............23
2.1 Clinical Study Objectives .............................................................................................................23
2.1.1 Primary Efficacy Objectives and Endpoints .........................................................................23
2.1.2 Secondary Efficacy Objectives and Endpoints ......................................................................24
2.1.3 Exploratory Efficacy Objectives and Endpoints ...................................................................24
2.1.4 Safety Objectives and Endpoints ............................................................................................25
2.2 Clinical Hypothesis .......................................................................................................................26
3 OVERALL CLINICAL STUDY DESCRIPTION ..........................................................................26
4 CLINICAL STUDY DURATION AND TERMINATION ............................................................27
5 SELECTION AND DISPOSITION OF CLINICAL STUDY POPULATION ............................27
5.1 Number of Subjects ................................
.......................................................................................27
5.2 Clinical Study Population Characteristics ..................................................................................27
5.2.1 Inclusion Criteria ................................
.....................................................................................27
5.2.2 Exclusion Criteria ................................................................
....................................................28
5.3 Medical History .............................................................................................................................29
5.4 Previous and Concomitant Therapi[INVESTIGATOR_014] .........................................................................................30
5.4.1 Definition ..................................................................................................................................30
5.4.2 Categories .................................................................................................................................30
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 4of 795.4.3 Recording ..................................................................................................................................30
5.4.4 Author ized Concomitant Therapi[INVESTIGATOR_014] .......................................................................................30
5.4.5 Prohibited Concomitant Therapi[INVESTIGATOR_014] ........................................................................................31
5.5 Procedures/Reasons for Subject Discontinuation ......................................................................31
6 CLINICAL SUPPLIES ......................................................................................................................33
6.1 Clinical Supply Identification and Use ........................................................................................33
6.1.1 AbobotulinumtoxinA ................................
...............................................................................33
6.1.2 Placebo ......................................................................................................................................33
6.1.3 Study Products(s) Description ................................................................................................[ADDRESS_522008] Identification Number (SIN) .....................................................................................34
6.1.5 Method of Treatment Assignment ..........................................................................................34
6.1.6 Kit Number/Randomization Number ....................................................................................35
6.1.7 Instructions for Use and Administration ...............................................................................35
[IP_ADDRESS] Study Products ....................................................................................................................35
[IP_ADDRESS].1 .....................................................................................35
[IP_ADDRESS].2 ............................................................................................................................35
[IP_ADDRESS] Treatment Preparation ......................................................................................................35
[IP_ADDRESS] Injection Technique ............................................................................................................36
[IP_ADDRESS] Treatment Procedure .........................................................................................................37
[IP_ADDRESS] Post- treatment Care ...........................................................................................................37
[IP_ADDRESS] Treatment Regimen ............................................................................................................37
[IP_ADDRESS] 38
6.2 Study Products(s) Packaging and Labeling ................................................................................38
6.3 Supplies Management ...................................................................................................................38
6.3.1 Accountability ..........................................................................................................................38
6.3.2 Storage of Study Products(s) ................................................................
...................................[ADDRESS_522009] Quality Complaints ...................................................................................................39
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 5of 796.4 Blinding ..........................................................................................................................................39
6.4.1 Verificati on of Blinding ...........................................................................................................39
6.4.2 Unblinding During the Clinical Study ...................................................................................40
7 CLINICAL STUDY ASSESSMENT ................................................................................................40
7.1 Efficacy Assessments .....................................................................................................................40
.....42
7.2 Safety Assessment ................................................................
.........................................................42
7.2.1 Focused Physical Examination ...............................................................................................
42
7.2.2 Adverse Events .........................................................................................................................43
[IP_ADDRESS] Definitions ................................................................
............................................................43
[IP_ADDRESS].1 Adverse Events (AE) ........................................................................................................43
[IP_ADDRESS].2 Treatment Emergent Adverse Event (TEAE) ...................................................................44
[IP_ADDRESS].3 Serious Adverse Events (SAE) .........................................................................................44
[IP_ADDRESS].4 Unexpected Adverse Drug Reaction ................................................................................44
[IP_ADDRESS].5 Adverse Event Reporting Period .....................................................................................45
[IP_ADDRESS].6 Severity ............................................................................................................................45
[IP_ADDRESS].[ADDRESS_522010] and/or Clinical Study Procedure ..............................45
[IP_ADDRESS] Reporting Procedures .........................................................................................................46
[IP_ADDRESS].1 Procedures for Reporting Adverse Events .......................................................................46
[IP_ADDRESS].2 Procedure for Reporting a Serious Adverse Event ..........................................................47
[IP_ADDRESS].[ADDRESS_522011] .........................................................................................................................49
7.4 Appropriateness of Measurements ..............................................................................................
49
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:[ADDRESS_522012] Instructions ......................................................................................................................56
9 STATISTICAL METHODS PLANNED .........................................................................................56
9.1 Statistical and Analytical Plans ................................
...................................................................56
9.1.1 Data Transformations .............................................................................................................56
9.1.2 Populations Analyzed and Evaluability .................................................................................56
[IP_ADDRESS] Intent -to-treat (ITT) Efficacy Population .........................................................................56
[IP_ADDRESS] Per-protocol (PP) Efficacy Population ..............................................................................56
[IP_ADDRESS] Safety Population ................................................................................................................56
[IP_ADDRESS] Imputation of Missing Data ...............................................................................................57
9.1.3 Data Presentation and Graphics .............................................................................................57
[IP_ADDRESS] Safety Analysis ....................................................................................................................57
9.1.4 Withdrawals and Deviations ...................................................................................................58
9.1.5 Inferential Statistical Analyses ...............................................................................................58
9.2 Sample Size Determination ..........................................................................................................59
9.2.1 Historical Data .........................................................................................................................59
9.2.2 Assumptions ................................................................
.............................................................59
9.2.3 Samp le Size Calculation ..........................................................................................................59
9.2.4 Interim Analysis .......................................................................................................................59
10 TRAINING / MONITORING / DATA MANAGEMENT / QUALITY ASSURANCE ..............60
10.1 Personnel Training ................................................................
........................................................60
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 7of 7910.2 Clinical Monitoring .......................................................................................................................60
10.3 Data Management ................................................................
.........................................................60
10.4 Quality Assurance/Audit/Inspection ...........................................................................................[ADDRESS_522013]/Amendments ................................
.....................................[ADDRESS_522014] CONSIDERATIONS ..................61
11.1 Independent Ethics Committee (IEC) or Institutional Review Board (IRB) ..........................[ADDRESS_522015] ................................
................................................................67
13 APPENDICES ....................................................................................................................................68
78
14 SIGNED AGREEMENT OF THE CLINICAL STUDY PROTOCOL ........................................79
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 15of 79CLINCIAL STUDY SCHEMATIC AND FLOW CHART
Table 1 Clinical Study Schematic
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 16of 79
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 17of 79
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
Version: Effective date: Effective
 2019-01-24 15:42
1.0
Print date:
 2021-03-30 20:23

Page 18of 79
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
Version: Effective date: Effective
 2019-01-24 15:42
1.0
Print date:
 2021-03-30 20:[ADDRESS_522016] OF ABBREVIATIONS AND DEFINITIONS OF TERMS
Abbreviation Term
C Degrees Celsius
AE Adverse Event
ADR Adverse Reaction
BOCF Baseline Observation Carried Forward
BoNT Botulinum Toxin
BoNT -A Botulinum Toxin Ty pe A
BoNT -A-HAC Botulinum Toxin Ty pe A -Haemagglutinin Complex
CDMS Clinical Data Management Sy stem
CM Concomitant Medication
CMH Cochran -Mantel -Haenszel
CPM Clinical Project Manager
CRF/eCRF Case Report Forms/electronic Case Report Forms
CRO Contract Research Organization
CSP Clinical Study  Protocol
DC Discontinuation
DMP Data Management Plan
EDC Electronic Data Capture
e.g. For Example (Latin: exempli gratia)
ET Early Termination
etc Et cetera
FDA Food and Drug Administration
FSFV First Subject First Visit (date of first subject included i.e., informed 
consent signature)
GAIS Global Aesthetic Improvement Scale
GCP Good Clinical Practice 
GL Glabellar Lines
HIPAA Health Insurance Portability  and Accountability  Act of 1996
IA Interim analysis
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council for Harmonisation
i.e. That is (Latin: id est)
IEC Independent Ethics Committee 
ILA Investigator Live Assessment
IND Investigational New Drug
IRB Institutional Review Board
IRT Interactive Response Technology
ITT Intent -to-treat
IUD Intrauterine Device
KM Kaplan -Meier
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:[ADDRESS_522017] Visit (date of last subject included i.e., informed 
consent signature)
LSLV Last Subject Last Visit (date of last subject’s last study  visit)
MD Medical Doctor
MedDRA Medical Dictionary  for Regulatory  Activities
MI Multiple I mputation
mL Milliliter
N or n Number
N/A Not Applicable
NaCI Sodium Chloride
OC Observed Cases
OTC Over -the-Counter
PE Physical Examination
PP Per-Protocol
PQC Product Quality  Complaint
SAE Serious Adverse Event
SIN Subject I dentification Number
SOC System Organ Class
SOP Standard Operating Procedure
SSA Subject Self -Assessment
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
TOC Table of Contents
TEAE Treatment Emergent Adverse Event
U Units
UPT Urine Pregnancy  Test
US [LOCATION_002]
USP [LOCATION_002] Pharmacopeia
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 21of 791 BACKGROUND AND RATIONALE
1.1 Medical Background and Short Rationale for the C linical Study
Botulinum toxin (BoNT) is a potent neurotoxic protein produced by [CONTACT_77255] -positive 
anaerobic bacterium, Clostridium botulinum. The molecule is produced naturally  by [CONTACT_77256] a series of accessory  proteins, forming what is termed the “toxin 
complex”. The neurotoxin is the cause of the severe and potentially  fatal disease of botulism. In 
addition, the protein is used in very small quantities as a treatment modality  for aestheti c and 
medical indications, many of which are characterized by [CONTACT_77257] . Botulinum 
toxins occur in seven known serot ypes (A-G) that are produced by [CONTACT_414221] . Clinically  important biologic activit y is limite d primarily  to the A and B 
seroty pes, of which the type A serot ype (BoNT -A) is used widel y throughout the world for the 
treatment of a range of clinical conditions. BoNT -A blocks the release of acetylcholine into the 
neuromuscular junction (synapse) cleft, thereby  [CONTACT_414222]. Paresis by  [CONTACT_414223], leading to inhibition 
of muscular contraction.
In the early 1990s, patients treated with BoNT -A for blepharospasm were observe d to lose their 
frown lines ,1,2and since publishing these observations, the use of BoNT -A in the aesthetic setting 
has accelerated. Injectable BoNT -A products have been investigated for multiple aesthetic 
indications in attempts to reverse the appearance of aging, especiall y in the facial region.1In the 
treatment of facial lines, the effect of BoNT -A injections usual ly persists for approximately 
4-[ADDRESS_522018]-
treatment.3
AbobotulinumtoxinA (Dysport) was approved by [CONTACT_72563] (FDA) in [ADDRESS_522019], a total of 50 Uis given intramuscularl y in five equal aliquots of 10 Ueach into each of 
five sites, two in each corrugator muscle and one in the procerus muscle. Re-treatments should 
be administered no more frequentl y than every three months. 
The rationale of the study  is to evaluate the currentl y approve d abobotulinumtoxinA dose of 
50 U using a larger injection volume of 0.1 mL per injection site for the treatment of moderate 
to severe glabellar lines. This injection volume provides better control of the injection, 
minimized the margin of error, and is comparable to other BoNT -A preparati ons, (i.e., 
onabotulinumtoxinA [Botox®] and incobotutinumtoxinA [ Xeomin®]). Based on anecdotal 
experience, it is also reflective ofcurrent clinical practice among some physicians and other 
qualified medical professionals.
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:[ADDRESS_522020] been stopped within the 4 weeks preceding 
the screening visit or within timeframes specified in the inclusion/e xclusion criteria .
Concomitant therapi[INVESTIGATOR_83778]:
any existing therapi[INVESTIGATOR_77222],
any changes to existing therapi[INVESTIGATOR_014] (such as changes in dose or formulation) during the 
course of the clinical study , or
any new therapi[INVESTIGATOR_77223].  
5.4.2 Categories
The following two categories are to be considered for p revious and concomitant therapi[INVESTIGATOR_014]: 
Drugs including but not limited to, prescription, over -the-counter (OTC), birth control 
pi[INVESTIGATOR_3353]/patches/hormonal devices, vitamins, herbal medicines/supplements, and homeopathic 
preparations.
Medical and surgical procedure sincluding, but not limited to, laser/radiation procedures, 
dermal fillers (area of treatment should be indicated), X- rays, surgeries, tooth extractions .
5.4.[ADDRESS_522021]’s source documents and
eCRF s.
Concomitant therapi[INVESTIGATOR_414214] . 
Any new concomitant therapy  or modification of an existing therapy  may be linked to an AE.  A 
corresponding AEform should be completed to account for the change in therapy, except in some 
cases such as therap y used for proph ylaxis, dose modification for a chronic condition, etc.
5.4.4 Authorized C oncomitant T herapi[INVESTIGATOR_77225] (see Section 5.4.5 ), all are authorized.
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 31of 795.4.5 Prohibited Concomitant T herapi[INVESTIGATOR_414215]/or safet y 
assessment of the stud y products(s):
Botulinum toxin of any  seroty pe.
Any other investigational new drug or device .
Any absorbable (temporary ) or non-absorbable (permanent) material above the lower 
orbital rim. 
Facial aesthetic procedures (e.gablative skin resurfacing, chemical peel,photorejuvenation 
or skin/vascular laser intervention) above the lower orbital rim .
Planned facial surgery  or ey e surgery  (including LASI K procedure).
Medications that affect neuromuscular transmission such as cur are-like depolarizing agents, 
lincosamides, poly myxins, anticholinesterases and aminogl ycoside antibiotics.
If a prohibited therapy  becomes a necessary  treatment for best clinical interest of the subject or 
due to safet y reason , the Medical Monitor (Sectio n 11.9)should be notified , if time permits, to 
discuss possible alternatives prior to administration of a prohibited therap y.
If a subject receives a prohibited therapy  during the clinical study , the Medical Monitor (Section 
11.9) should be notified to discuss the subject’ s continuation in the clinical study ..
5.5 Procedures/Reasons for Subject Discontinuation
An Investigator may  decide to discontinue a subject from the clinical study for safety  reasons.
Although the importance of completing the entire clinical study should be explained to the 
subject by [CONTACT_77262], any subject is free to discontinue participation in this 
clinical study at any time and for whatever reason, specified or unspecified, and without any 
prejudice.  No constraints are to be imposed onthe subject, and when appropriate, a subject may 
be treated with other conventional therap y when clinically  indicated. 
When a subject does not complete the clinical study , he/she will be fully  assessed, if such 
assessment is possible.  The procedures designated for the Month 6/ETvisit should be completed 
for all subjects discontinuing the clinical study and the appropriate eCRF shou ld be completed.
All discontinuations and the reason for discontinuation are to be documented by [CONTACT_414224]. For discontinuation due to an AE, the AE form is to be completed. The 
Investigator should also ensure that the subject receives suitable therap y for the AE.
Potential reasons for discontinuation, as listed on the exit form, are defined below:
Adverse Event: Complete an AE form.
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 32of 79Withdrawal by  
[CONTACT_27720]:Includes consent withdrawal, subject relocation, schedule conflicts, 
etc.  Explain the reason for withdrawal in the comment section of the 
eCRF exit form.
Lost to Follow -up: Confirmed with two documented phone calls and a certified letter 
(delivery  receipt requested) without answer.  Explain in the comment 
section of the eCRF exit form.
Other: This category  is to be used for a subject who discontinues due to a 
reason other than as specified in the predefined categories above.  
Explain the reason for discontinuation in the comment section of the 
eCRF exit form.
A subject who has been randomized and assigned a kitnumber/randomization number cannot be 
replaced by [CONTACT_414225]/she discontinues the clinical study for any reason. Additional 
subjects could be enrolled (randomized/assigned to treatment) in order to attain the number of 
evaluable subjects.
Pregnancies occurring during the screening period are considered screen failures; they should be 
recorded as such in the eCRF and no pregnancy  form is to be completed. In case of a pregnancy  
occurring after the baseline visit, follow the procedures described in Section [IP_ADDRESS].[ADDRESS_522022] may remain in the study , but no invasive procedure should be conducted (e.g. no sample 
taken for lab test).
The Sponsor may also decide to prematurely  terminate or suspend a subject’s participation in the 
clinical study .
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 39of 79In the event of early termination/suspension of the clinical study , a rapid recall of study 
products (s) will be initiated.  
6.3.[ADDRESS_522023] Qualit y complaints (PQCs) should be reported to the Sponsor Contact [INVESTIGATOR_1461] 
(Section 11.9). A PQC is an external judgement presuming a quality  defect of a product; quality 
issue for a product relating to its presentation or use, identified by a  subject, a practitioner or 
investigator site personnel, a distributor, or anyone else involved in clinical supplies handling. 
Examples may  include but are not limited to appearance issues, odor, damaged stoppers, low fills, 
and foreign matter in the product. These complaints may or may not represent a potential risk to 
the subject. A PQC form must be com pleted by [CONTACT_414226] [ADDRESS_522024] details are provided in the Inve stigator’s site file.
6.[ADDRESS_522025]'s study  product assignment. 
Preparation and administration of the study  products, abobotulinumtoxinA or placebo , will be 
completed in exactly  the same way .
An un-blinded statistician will generate the randomization schedule; however, they will not be 
involved in any  other aspect of the study  prior to database lock.
6.4.1 Verification of B linding
The Sponsor’s staff or designees will assess and verify  maintenance of the study  blind during the 
study  through routine monitoring visits. 
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:[ADDRESS_522026] be provided with the name [CONTACT_414239].
[IP_ADDRESS] Definitions
[IP_ADDRESS].1 Adverse Events (AE)
According to ICH E2A, an AE is any untoward medical occurrence in a patient or a clinica l 
investigation subject administered a pharmaceutical product and which does not necessarily  have 
a causal relationship with this treatment. An AE can therefore be any  unfavorable and unintended 
sign (including an abnormal laboratory  finding), symptom, or disease temporally  associated with 
the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
Thus any new sign, symptom or disease, or any clinically  significant worsening of an existing 
sign, symptom or disease (including new epi[INVESTIGATOR_4101] a chronic disease [e.g., hay fever, allergy ]) 
compared to the condition at the first visit, should be considered as an AE. Lack of efficacy  is not 
considered as an AE.
Notes:
There should be an attempt to report adiagnosis rather than the signs, symptoms or 
abnormal laboratory  values associated with the report of an AE. However, a diagnosis 
should be reported only  if, in the investigator’s judgment, it is relatively  certain. Otherwise, 
symptoms, signs, or laborato ry values should be used to describe the AE.
Pregnancy  is not to be considered as an AE; however, is an important medical event that 
must be monitored as described in Section [IP_ADDRESS].3 .
The effects of Dysport and all BoNT products may spread from the area of injection to 
produce symptoms consistent with BoNT effects. These symptoms have been reported 
hours to weeks after injection. Remote spread of toxin that affects swallowing and 
breathing can be life threatening, and there have been reports of death. The risk of 
symptoms is increased insubjects who have underly ing conditions (e.g. disorders of the 
neuromuscular junction) that would predispose them to these symptoms. Dysport is 
contraindicated in individuals with known hypersensitivity  to any BoNT preparation or to 
any of the components in the formulation. 
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 44of [IP_ADDRESS].2 Treatment Emergent Adverse Event (TEAE)
A TEAE is an event that emerges during treatment, having been absent pre -treatment, or worsens 
relative to the pretreatment state.
Investigators are responsible for monitoring, recording, and reporting all AEs that occur during 
the study  as described . TEAEs will be delineated from AEs following database lock.
[IP_ADDRESS].3 Serious Adverse Events (SAE)
A SAE is any untoward medical occurrence that at any  dose:
Results in death,
Is life -threatening,
Requires inpatient hospi[INVESTIGATOR_1081],
Results in persistent or significant disability /incapacity , or
Is a congenital anomal y/birth defect.
Important medical events that may not result in death, be life-threatening, or require 
hospi[INVESTIGATOR_10154], based upon appropriate medical judgment, they 
may jeopardize the safety of the subject, and may require medical or surgical intervention to 
prevent one of the outcomes listed in this definition.  Examples of such events are intensive 
treatment in an emergency  room or at home for allergic bronchospasm, blood dyscrasia, or 
convulsions that do not result in hospi[INVESTIGATOR_059].
Note: The term “life -threatening” refers to an event in which the subject was at risk of death at 
the time of the event; it does not refer to an event which hypothetically  might have caused death 
if it were more severe.
Inpatient hospi[INVESTIGATOR_414216] a night at 
the hospi[INVESTIGATOR_307].  The criterion for prolongation of hospi[INVESTIGATOR_414217].  Hospi[INVESTIGATOR_414218] a diagnostic test(s)(even if related to an AE), elective 
hospi[INVESTIGATOR_77234], admission to a day-care facility , social admission (e.g., if the subject has no place 
to sleep), or administrative admission (e.g., for a y early  examination).
[IP_ADDRESS].[ADDRESS_522027] information (e.g., Investigator’s 
Brochure for an unapproved investigational product or the medicinal package insert/summary  of 
product characteristics for an ap proved investigational product).
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 45of [IP_ADDRESS].[ADDRESS_522028]’s participation.
The Sponsor should be informed if the Investigator becomes aware of any unusual safety 
information or any safet y information that appears to be drug -related involving a subject who has 
participated in a clinical study , even after a subject has completed the clinical study .  
[IP_ADDRESS].[ADDRESS_522029] appropriate according tohis/her
medical judgment.
Mild Awareness of signs or s ymptom, but easily  tolerated.
Moderate Discomfort, enough to cause interfer ence with usual activity .
Severe Incapacitating with inability  to work or perform usual activity .
[IP_ADDRESS].[ADDRESS_522030] and/or C linical Study P rocedure
The Investigator is to determine whether there is a reasonable causal relationship between the 
occurrence of the AE and exposure to the study  product and/or clinical study  procedure .
Medical judgment should be used to determine the relationship, consideri ng all relevant factors 
including the pattern of reaction, temporal relationships, relevant medical history , and 
confounding factors such as co -medication or concurrent diseases.
The expression “reasonable causal relationship” is meant to convey  in general that there are facts 
or arguments to suggest a causal relationship (I CH E2A, Section IIIA 1).
The relationship assessment for an AE is to be completed using the following definitions as a 
guideline:
Reasonable P ossibility:
According to the reporting Inves tigator, there is a reasonable possibility  (i.e., suggestive evidence 
or arguments) that there is a causal relationship irrespective of the dose administered between:
The study  product (active or placebo ) and the AE .
The clinical study  protocol procedure (e.g., bruising or marks from blood draws, injection 
related trauma, etc.) and the AE .
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 46of 79A two-point scale (Yes or No response) shall be used for the causality  assessment. The 
Investigator shall be asked to indicate a response to each of the following questi ons in the eCRF:
“Do you consider that there is a reasonable possibility  that the event may have been caused 
by [CONTACT_414227]?”, and 
“Do you consider that there is a reasonable possibility  that the event may have been caused 
by [CONTACT_414228]?”
If any of these questions is answered Yes, the AE is considered related. 
No Reasonable Possibility:
No suggestive evidence or arguments can be identified regarding a causal relationship between 
the study  product or the clinical study  protocol procedure and the AE.
[IP_ADDRESS] Reporting P rocedures
[IP_ADDRESS].[ADDRESS_522031]-enrollment visit, the Investigator (or sub-Investigator) will question the subject 
about AEs using an open non-persuasive question to elicit reporting of AEs, for example “Have 
you noticed any change in your health since the last visit?”  Directed questioning and 
examination will then be performed as appropriate. 
Any AE occurring during the AE reporting period, whether it is related to the study  product or 
not, will be recorded immediately  in the source document, and described on the AE form of the 
eCRF along with the date of onset, severit y, relationship to the study  product , and outcome, 
without omitting any  requested and known information.  Additional information will be requested 
under certain circumstances.  
Adverse Events (AEs) assessed as related to the treatment or study  procedure will be monitored 
until they  have resolved or reached a stable condition.  Other AEs will be monitored until the last 
visit if they  have not resolved or reached a stable condition. 
The Investigator will obtain and maintain in the subject’s files all pertinent medical records, 
informat ion and medical judgment from colleagues who assisted in the treatment and follow -up 
of the subject.  If necessary , the Investigator will contact [CONTACT_423]’s personal physician or 
hospi[INVESTIGATOR_99391].
For SAEs (see Section [IP_ADDRESS].2 ) and pregnancies (see Section [IP_ADDRESS].3 ), the Sponsor is to be 
informed immediatel y by e-mail.  The event must be reported by e-mail to the Safet y Mailbox 
within 24 hours of receipt of the information (contact [CONTACT_77268] [IP_ADDRESS].2 ).
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 47of [IP_ADDRESS].[ADDRESS_522032] do the following:
1. Take prompt and appropriate medical action, if necessary .  The safet y of the subject is the 
first priority .
2. Ensure that the event is classified as an SAE (Section [IP_ADDRESS].3 ).
3. Complete the AE form provided in t heeCRF as fully as possible.
Print and complete the SAE form .  E-mail the completed form, accompanied by [CONTACT_414229] (e.g., laboratory  test results) within 
24hours of receipt of the information toSafet y Mailbox listed below . The demographics, 
medical history , drugs/t herapi[INVESTIGATOR_77235], medical and surgical procedures form, and AE pages 
of the eCRF must be completed and available for review in the EDC system at the time of 
the report.
4. Immediately  send the completed SAE report form to the Safety  Mailbox via e-mail and 
discuss further actions to be taken.
Addi tional contact [CONTACT_414230]’s site file.
5. Monitor and record the progress of the event until it resolves or reaches a clinically  stable 
outcome, with or without sequelae.  For all additional follow -up evaluations, send by  e-mail 
all additional follow -up information on the SAE to the Safet y Mailbox within 24hours of 
receipt of the updated information.  SAEs will be monitored until the Investigator and 
Sponsor agree that the event is satisfactorily  resolved.
6. Obtain and maintain in his/her files all pertinent medical records, information, and medical 
judgments from colleagues who assisted in the treatment and follow -up of the subject.  If 
necessary , contact [CONTACT_423]’s personal phy sician or hospi[INVESTIGATOR_99391].
7. Inform the Sponsor of the final outcome of the event.  Send a revised or updated SAE form 
and AE f orm, if appropriate to the Safet y Mailbox.
8. Prompt notification of SAEs by [CONTACT_414231]. The Sponsor 
has a legal responsibility to notify  both the local regulatory  authorit y and other regulator y 
agencies about the safety  of a product under clinical investigation. The Sponsor will 
comply  with country  specific regulatory  requirements relating to safety  reporting to 
regulatory  authorities, Institutional Review Boards (IRBs),and Investigators. Investigator 
safet y reports are prepared for Suspected Unexpected Serious Adverse Reactions 
(S[LOCATION_003]Rs ) according to local regulatory  requirements and the Sponsor policy  and are 
forwarded to Investigators as necessary . An Investigator who receives an Investigator 
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 57of [IP_ADDRESS] Imputation of M issing Data
The Observed Cases (OC) will be used for all safety  analyses as well as the exploratory  analyses. 
The primary  ITT analysis will be performed using baseline observation carried forwar d (BOCF), 
and repeated using multiple imputation (MI) for missing values. The secondary  efficacy  analyses 
will be performed using BOCF. If deemed necessary , any analyses may be repeated using OC, 
BOCF, or MI as appropriate.
9.1.3 Data Presentation and G raphics
All statistical analy ses, including summary  tables and data listings, will be performed using the 
SAS®system (version 9).
Subject disposition, completion and discontinuation by [CONTACT_15449], protocol deviations, 
demographics and baseline characteristics, medical history , medical and surgical procedures, 
prior and concomitant medications, will be summarized by  [CONTACT_1570].
All efficacy  variables will be summarized by [CONTACT_99432].  The categorical variables 
will be summarized by [CONTACT_414232]  (N, %).  
The continuous variables will be summarized using n (number of observations), mean, median, 
minimum, maximum, and standard deviation for the data collected at each visit. 
For anal ysis of duration of effect and time to onset of treatment response, Kaplan -Meier plots and 
estimates of the median event times will be used. Responder rates over time will be presented in 
graphs.
All study  data will also be listed in subject data listings. Graphs will be util ized as appropriate.
[IP_ADDRESS] Safety Analysis
AEs will be summarized descriptively  by [CONTACT_1570], SOC and PT using number and 
percentage of subjects with at least oneevent and number of events. The results will be further 
broken down by [CONTACT_414233] y, causality , seriousness, and whether the event led 
to discontinuation. Duration and time to onset ofrelated AEs will also be presented by [CONTACT_6490], SOC and PT.
The numbers and percentages of subjects with abnormalities in physical examinat ion will also be 
summarized. The results of the urine pregnancy  tests will be listed.
All AEs will be monitored by[CONTACT_414234] . A list of preferred terms forthese types of events will be 
provided in the SAP, andwill be further analyzed to determine if there is a plausible possibility  
that they represent distant spread oftoxin or hypersensitivity . In order to perform the analysis, 
variables including alterna tive etiology  (medical history , concomitant medication, or diagnosis 
which could account for thesymptoms), location of Dysport administration, and temporal 
relationship to Dy sport administration will be considered by  [CONTACT_941] S ponsor.
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 60of 7910 TRAINING / MONITORING / DATA MANAGEMENT / QUALITY ASSURANCE
10.[ADDRESS_522033] of the clinical study  will be closely monitored by [CONTACT_414235], ICH -GCP guidelines, and applicable SOPs.  
The Investigator will allow the CRO/Sponsor’s representatives, to have direct access to all 
clinical study records, CRFs, corresponding subject medical records, study  product (s) dispensing 
records, and any other documents considered source documentation.  Additionally , the 
CRO/Sponsor representative is to have access to the study  product storage area and clinical study
facilities.
The Investigator also agrees to assist the representative if required.
10.3 Data Management
All data management procedures will be detailed in a Data Management Plan (DMP). 
The DMP will describe the Clinical Data Management System (CDMS) that will be used to 
collect data (either EDC or paper CRF), and whether the data management activities are 
performed internally  or outsourced.  Computerized edit checks and review processes will be 
performed on an ongoing basis as outlined in the DMP until all data clarifications are resolved.  
The data will be exported to be stored in SAS datasets.  After all data clarifications are resolved, 
coding is approved, SAE/pregnancy  reconciliation has been completed (if applicable) and 
subject’s evaluabilit y is determined, the database will be locked.
10.4 Quality Assurance/Audit /Inspection
The clinical study is conducted under the sponsorship of the Sponsor in compliance with the 
applicable international and local regulatory  requirements as well as applicable ICH guidelines 
and in accordance with the SOPs for clinical study conduct and monitoring from the Sponsor 
and/or the Contract Research Organization (CRO).
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 61of 79Audits of clinical study centers may be conducted by [CONTACT_1034]/CRO representatives, and 
inspection may  be performed by  [CONTACT_414236]/IECs before, during, 
or after the clinical study .  
The Investigator will allow and assist the CRO/Sponsor’s representatives, IRBs/IECs and any 
regulatory  agency  to have direct access to all requested clinical study -related records.
For the audits performed by, or on behalf of, the Sponsor auditors, audit certificate(s) will be 
provided b y Quality Assurance.
10.[ADDRESS_522034]/A mendments
10.5.[ADDRESS_522035], the Investigator should not 
deviate from the clinical study protocol or implement any changes without written approval from 
the Sponsor and prior review and documented approval/favorable opi[INVESTIGATOR_5698]/IEC of a 
protocol amendment.
Changes that involve only logistical or administrative changes to the clinical study protocol are 
authorized.  The Investigator should document and explain any deviation from the clinical study
protocol.
10.5.[ADDRESS_522036] CONSIDERATIONS
11.1 Independent Eth ics Committee (IEC) or Institutional Review Board (IRB)
This clinical study protocol and all amendments will be reviewed and approved by [CONTACT_414237]/I RBs.
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:[ADDRESS_522037] of the Clinical Study
This clinical study will be conducted in accordance with the protocol ,the HEL SINKI declaration 
(1964) and subsequent amendments, and the ICH GCP, and in compliance with applicable 
regulatory  requirements. 
11.[ADDRESS_522038] I nformation and Consent
All subjects who participate in this clinical study  are required to be fully  informed about the 
clinical study in accordance with GCPs guidelines, federal regulations, HIPAA ,and guidelines 
and in accordance with local requirements.  
The ICF(inclusive of HIPPA and photo consent ), approved by [CONTACT_2717]/IEC, will be fully  
explained to the subject.  The subject must agree to photo consent in order toparticipate in the 
clinical study . 
Prior to enrol lment into the clinical study , the subject and the PI [INVESTIGATOR_77239](s).  The Investigator is responsible for maintaining each subject’s consent 
form(s) in the Investigator’s site file and providing each subject with a copy  of the signed and 
dated consent form(s).
11.4 Protection of Personal Data
The completion of the study  involves the gathering and processing of Personal Data as specified 
in the Regulation (EU) 2016/[ADDRESS_522039] of 1996 (HIPAA), as provided at CFR § 512(b)(iii), and the study  subject should be 
made aware of this exception in the informed consent. The Sponsor shall, to the extent feasible, 
protect study  subject identifier information.
The Institution and Principal Investigator [INVESTIGATOR_414219] . Such consent shall include the consent to the transfer of Personal Data to 
government authorities located in countries outside the US. 
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:[ADDRESS_522040] withdrawn from the study but the data collected until the consent was 
withdrawn may  be used in the statistical analy ses.
All collecti on, processing and analyses of protected health information, personal data or similar 
will be conducted in compliance with applicable local, national and international rules, 
regulations and guidelines.
11.5 Contractual R equirements
A contractual agreement will be signed between the CRO/Sponsor and each 
Investigator/Institution.  This document will contain supplementary  information, including 
financial terms, confidentiality , the clinical study schedule, third party  responsibility , and 
publication rights.
11.[ADDRESS_522041]’s source documents and in the eCRFs provided by [CONTACT_1034].  
All data should be recorded i n the e CRFs completely  and promptly .
11.6.[ADDRESS_522042] keep accurate separate records (other than the eCRFs) of all subject visits, 
being sure to include all pertinent cli nical study -related information.  A statement should be made 
indicating that the subjects have been included in this clinical study and have provided signed 
written Informed Consent.  All AEs must be thoroughl y documented.
Results of any diagnostic tests conducted during the clinical study should also be included in the 
source documentation.  
11.6.3 Archives
All pertinent data, samples, photographs, correspondence, and reports, the original or amended 
clinical study protocol, and all other material relating to the clinical study will be maintained 
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 65of 79
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 66of 79
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:[ADDRESS_522043]
1.Monheit, G. D. and A. Pi[INVESTIGATOR_41274] (2017). "AbobotulinumtoxinA: A 25-Year History ." Aesthet 
Surg J 37(suppl_1): S4 -s11
2.Carruthers, J. and A. Carruthers (2007). "The evolution of botulinum neurotoxin type A for 
cosmetic applications." J Cosmet L aser Ther 9(3): 186-192.
3. R zany, B., D. Dill-Muller, D. Grablowitz, M. Heckmann, D. Caird and G. German -Austrian 
Retrospective Study  (2007). "Repeated botulinum toxin A injections for the treatment of lines 
in the upper face: a retrospective study  of 4,103 treatments in 945 patients." Dermatol Surg 
33(1 Spec No.): S18-25.
4.Dysport (BTX -A-HAC Powder) Aesthetic Indications Investigator’s Brochure , version 6.0, 
28Aug 201 8: Ipsen Group.
5.DYSPORT®(abobotulinumtoxinA) for injection US Pre scribing Information (2017).
6.Pusic, AL., AF. Lassen, AM. Scott, SJ. Cano (2013) “Development and psychometric 
evaluation of the FACE -Q satisfaction with appearance scale: a new patient -reported outcome 
instrument for facial aesthetics patients.” Clin Plast Surg. Apr;40(2):249- 60.
7.Klassen, AF., SJ Cano, AM. Scott, AL. Pusic (2014) “Measuring outcomes that matter to 
face-lift patients: development and validation of FACE -Q appearance appraisal scales and 
adverse effects checklist for the lower face and neck.” Plast Reconstr Surg. Jan;133(1):21-30.
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 69of 79
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 70of 79
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 71of 79
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 72of 79
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 73of 79
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 74of 79
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 75of 79
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 77of 79
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Page 78of 79
Title  Doc id  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23

Sign page: 1 of 1SIGNATURES PAGE
Date Signed by
2019-01-24 00:57
Justification Approved by [CONTACT_77285]
2019-01-24 07:58
Justification Approved by [CONTACT_77285]
2019-01-24 08:49
Justification Approved by [CONTACT_414238]
2019-01-24 15:42
Justification Compi[INVESTIGATOR_414220]  
43USD1805 Clinical Study Protocol Dysport New Dilution GL
   Effective date:   Version: Effective
 2019-01-24 15:42
1.0
  Print date:
 2021-03-30 20:23
